DHTKD1 and glioma: Another AV, DNX-2401 (DNAtrix), with partial E1A gene deletion in retinoblastoma (Rb)-binding domain and integrin receptor arginine-glycine-aspartic acid (RGD)-4C insertion, which may act against glioma, was designed by FDA as an orphan drug.